Lysosomal acid a-glucosidase (1,4-a-D-glucan glucohydrolase; EC 3.2.1.20) is an exo-1,4-a-D-glucosidase that hydrolyzes both a-1,4 and a-1,6 linkages of oligosaccharides, liberating glucose. It catalyzes the complete degradation of glycogen, with slowing at branching points. The 28-kb acid a-glucosidase gene on human chromosome 17 encodes a 3.6-kb mRNA which produces a 951-aa polypeptide (1, 2) . The enzyme receives cotranslational N-linked glycosylation in the endoplasmic reticulum. It is synthesized as a 110-kDa precursor form, which matures by extensive modification of its glycosylation, phosphorylation, and proteolytic processing through a 90-kDa endosomal intermediate into the final lysosomal 76-and 67-kDa forms (1, (3) (4) (5) .
In Pompe disease, a deficiency of acid a-glucosidase causes massive accumulation of glycogen in lysosomes, disrupting cellular function (6) . In the most common infantile form, patients exhibit progressive muscle degeneration and cardiomyopathy and die before 2 years of age. Intravenous injection of enzyme obtained from human placenta or Aspergillus niger corrected enzyme and glycogen levels in liver but not in muscle or heart in patients with Pompe disease (7) (8) (9) . Acid at-glucosidase is targeted to lysosomes via the mannose-6-phosphate receptor as well as by sequences associated with delayed cleavage of the signal peptide (6) . Mannose 6-phosphate-containing enzyme from bovine testes, human urine, or medium of transiently
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transfected COS cells is taken up efficiently by cultured patient cells through the mannose-6-phosphate receptor (3, (10) (11) (12) . Because of the high abundance of these receptors in heart and muscle, bovine testis enzyme injected intravenously into mice is targeted to these tissues (13) . Interspecies antigenicity requires the use of the human enzyme (7) . The low abundance in human urine makes this source impractical (10) . The isolation of a full-length acid a-glucosidase cDNA (1) makes production of recombinant human enzyme possible.
Recombinant human acid a-glucosidase made in bacteria was not catalytically active (14) , and that made in baculovirusinfected insect cells was active but was not taken up efficiently by a Pompe patient's fibroblasts (15 amplification using the primers GAA224(+) (5'-TCC-AGG-CCA-TCT-CCA-ACC-AT-3') and GAA751(-) (5 '-TCT-CAG-TCT-CCA-TCA-TCA-TCA-CG-3') determined in confluent cultures in 25-cm2 flasks after incubation for 2 days in medium with serum in which the acid a-glucosidase enzyme had been inactivated (1 hr at 56°C and pH 10). Cells were washed twice with phosphate-buffered saline, harvested by scraping, pelleted, and suspended in 130 ,ul of water. Cell lysates were prepared by brief sonication; the debris was pelleted by centrifugation, and glucosidase activity and total protein content were determined in the supernatant. Both cells and medium were analyzed, and the 10 highest-producing clones of pJW-5'sGAA were grown in 200 nM MTX. Resistant clones were further amplified with methotrexate. Clonal homogeneity was assured by repeated single-cell selection, using cloning rings initially and later followed by limiting dilution with selection for the highest producers. Stability of cell clones was examined after 3 weeks in culture without the selection agents. To optimize production, enzyme activity, glucose, and lactate in the medium were followed over 48 hr under various culture conditions (Iscove's medium, 5 mM butyrate, acidification of the medium to pH 6.6) in 25-cm2 confluent flasks with 0.2 ml of medium per cm2.
Enzyme Purification. Acid a-glucosidase was purified from human placenta (18) and human urine (10) . Antiserum to the placental enzyme was raised in rabbits. For purification of recombinant acid a-glucosidase, the method used for urinary enzyme was employed but with a 2.6 cm x 100 cm Sephadex G-200 column. After elution, enzyme-containing fractions were combined into four fractions. Following the addition of 0.1 volume of 0.65 M NaCl/0.5 M citrate, pH 6.50, they were concentrated in 10-kDa Centriprep cartridges (Amicon). To examine purity, 10 ,ug of total protein was analyzed by SDS/ PAGE and stained with Coumassie blue R. Denatured fractions (2 gl of enzyme boiled with 1% SDS) were deglycosylated overnight at 37°C with N-glycosidase F (0.5 unit; Boehringer Mannheim). The molecular weight of the enzyme in the CHO cells and culture medium under various culture conditions was analyzed by SDS/PAGE, Western blotting, and detection with rabbit anti-acid a-glucosidase antiserum and chemoluminescence (ECL; Amersham).
Enzyme Assays. Acid and neutral a-glucosidase were assayed using 4-methylumbelliferyl a-D-glucoside in a 96-well plate (19) . Acid fB-galactosidase, ,3-glucuronidase, and total hexosaminidase were similarly assayed with the respective 4-methylumbelliferyl derivatives (20) . a-Glucosidase activity was also measured by following the release of glucose from maltose or glycogen (21) . The glycogen content of fibroblast lysates was assayed by the release of glucose after digestion of 25 ,ll of boiled supernatant with 0.5 unit of Aspergillus niger amyloglucosidase at 37°C for 90 min. Total protein was measured by the Bradford method (22) .
Uptake of Acid a-Glucosidase by Fibroblasts, Liver, Muscle, and Heart. Fibroblasts from two patients with infantile Pompe disease, without measurable residual enzyme activity (<1 nmol/hr per mg of protein), were grown to confluency in Eagle's MEM containing 10% FBS in which acid a-glucosidase was inactivated. The uptake in fibroblasts was examined after incubation for 24 hr in medium with recombinant enzymeactivity at 1000 nmol hr-'ml-'. Mannose 6-phosphate (5 mM) was added to the medium to examine the effect of blockade of the mannose-6-phosphate receptor. To examine the effect on intracellular glycogen stores, the cells were incubated in Eagle's MEM without glucose or with glucose at 1 mg-ml-1, with 10% dialyzed FBS in which the acid a-glucosidase had been inactivated, and with or without purified enzyme activity at 1500 nmol-hr-1ml-1. To examine tissue localization of the enzyme in vivo, the remainder of fraction 11 (460 ,ll) was injected intravenously into an 8-day-old Hartley guinea pig, with two littermates as control. After 24 hr the animals were sacrificed and acid a-glucosidase activity was determined in Overall, the genetic manipulation of the CHO cells resulted in a 1340-fold increase of acid a-glucosidase intracellularly and a 3000-fold increase in the medium compared with the original untransfected CHO cells. At this level, 30% of all enzyme in the culture dish was intracellular, the rest being in the medium. The relative amount secreted increased with increasing levels of production. There was no increase in acid ,3-galactosidase, /3-glucuronidase, or hexosaminidase in the medium of the transformed cells. Clonally homogeneous cells resistant to 800 nM MTX showed stable expression in cells and medium after 3 weeks culture without Geneticin. But when cultured for 3 weeks without Geneticin and MTX, activity was reduced to the level before MTX amplification (intracellular, 17,583-nmol-hr-lmg-1; medium, 424 nmol hr-'ml-1).
Optimization of Acid a-Glucosidase Production. Reduction of the pH of the medium to 6.6 stabilized the enzyme and improved yield in MEM-a from 1135 to 4725 nmolbhr-'ml-'.
This effect was not seen with Iscove's medium. Butyrate increased acid a-glucosidase production both in cells and in medium when either MEM-a (intracellular, from 22,900 to 32,900 nmol-hr-lmg-1; medium, from 1140 to 3650 nmol hr-l ml-1) or Iscove's medium (intracellular, from 16,700 to 25,700 nmol-hr-'mg-1; medium, from 4200 to 7260 nmolhr-'ml-') was used. which time a maximum of lactate was achieved. The acid a-glucosidase level increased nearly linearly for 24 hr, then plateaued until 42-48 hr, after which the acid a-glucosidase level dropped and cell death occurred (Fig. 1A) (Fig. 2) . In contrast, the enzyme in the medium was almost completely the 110-kDa form. Culture conditions did not affect the molecular mass of the enzyme; only in MEM-a with 5 Tissue culture medium to which an equal volume of 0.5 M NaCl/0.05 M citrate, pH 6.5, was added was purified on a concanavalin A-Sepharose 4B column (Con A). The sample was concentrated and diafiltered with 25 mM NaCl/1 mM EDTA/20 mM acetate buffer, pH 4.5 (Con A conc.), before purification on a Sephadex G-200 column. The final concentrated product (Seph. conc.) is the sum of the four concentrated fractions (I-IV). Kinetic parameters were determined with 4-methylumbelliferyl a-D-glucoside as substrate.
nmol-hr-1 per mg of protein in the cells (13% of cellular protein).
Purification of Recombinant Enzyme. Acid a-glucosidase was retarded on the Sephadex G-200 column beyond the elution of bovine serum albumin, resulting in >200-fold purification with a recovery of >70% (Table 2) , with no additional bands visible by Coomassie staining (Fig. 3) . The first fraction contained almost uniquely the precursor 110-kDa form, while the later fractions contained increasing amounts of the 76-kDa form (Fig. 3) . The specific activity increased with the increased amount of the 76-kDa form ( Table 2 ). The diffuse nature of the bands on SDS/polyacrylamide gels suggested variable glycosylation. After deglycosylation with N-glycosidase F, the first fraction showed two bands at 100 and 95 kDa. The more mature 95-and 76-kDa forms in fractions 2 and 3 similarly showed a second band, at 90 and 68 kDa, respectively. Analysis of substrate kinetics with 4-methylumbelliferyl a-D-glucoside gave a linear Lineweaver-Burk plot and showed a lower Vma,, and lower Km for fraction 1 than for fractions II and III ( Table 2 ). The pH optimum of the enzyme for 4-methylumbelliferyl a-D-glucoside was 4.5, similar to enzyme purified from human urine and placenta. The pH optimum of the recombinant acid a-glucosidase was 4.5 for maltose and 4.25 for glycogen.
Correction of Patient's Fibroblasts and in Vivo Animal Experiment. Addition of tissue culture medium containing recombinant acid a-glucosidase at 1000 nmol-hr-lml-1 to fibroblasts from two patients showed uptake of the enzyme that reached the intracellular levels seen in normal fibroblasts. The uptake was >99% inhibited by 5 mM mannose 6-phosphate (Table 3) . After a 24-hr incubation of patient's fibroblasts with purified recombinant enzyme at 1500 nmol hr-l ml-1, the intracellular glycogen dropped to a level similar to that in normal control fibroblasts (Fig. 4) . This decrease was prevented by addition of mannose 6-phosphate to the medium. When glucosefree medium was used for 24 hr to reduce the contribution of cytoplasmic glycogen, a similar drop in intracellular glycogen was seen with recombinant enzyme. Twenty-four hours after intravenous injection of 4 mg of purified enzyme (fraction II) into a 124-g guinea pig, the acid a-glucosidase activity was strikingly higher in the liver and in the heart than in liver and heart of control animals (Table 4) .
DISCUSSION
Large amounts of human acid a-glucosidase are required for therapeutic trials in patients with Pompe disease. Shortening of the 5' end of the acid a-glucosidase cDNA increased the efficiency of expression of this enzyme. Use of a CMV promoter-driven expression vector with Geneticin selection and DHFR amplification allowed the development of a highproducing cell clone with only three rounds of amplification. This technique considerably shortens the time required with MTX alone. Increased production of recombinant lysosomal enzymes has been reported with the use of NH4Cl to interfere with lysosomal routing (23), with acidification of the medium to stabilize the lysosomal enzymes (24), and with butyrate, which increases transcription of stably transfected genes (25, 26) . In our work, treatment with NH4Cl did not improve the production (data not shown). Butyrate increased the production per cell, both in the cells and in the medium, but toxic effects limited its use to 48 hr. The low glucose content in MEM-a limited the production of recombinant enzyme to 24 hr. In high-glucose (4.5 mgml-') Iscove's medium, the response depended on the confluency. If sufficient cells were present at the initiation of the experiment, high production resulted from a combination of increased cell numbers (even Table 3 . Enzyme uptake in fibroblasts of patients with infantile Pompe disease Acid a-glucosidase activity, nmol-hr-lmg- Fibroblasts were incubated for 24 hr with acid a-glucosidase (activity, 1000 nmol hr-l ml-1) with or without 5 mM mannose 6-phosphate (M6P), and acid a-glucosidase specific activity was measured.
Normal control fibroblasts (n = 22) contained 255 nmol hr-l mg-1
(range 66-498). suspended in culture) and stabilization of the enzyme at the low pH by production of a large amount of lactic acid. Finally, combining Iscove's medium with cells at high confluency and butyrate for 48 hr proved optimal for enzyme production, with enzyme up to 91.4 ,tg/ml in the medium and constituting up to 13% of the cellular protein. This level supersedes previously published levels for production of lysosomal enzymes in mammalian cells (23-25, 27, 28). One possible explanation for the high production of enzyme was the extensive selection for subclones that not only accumulated the a-glucosidase intracellularly, but also secreted it efficiently into the medium. Cell clones with similar intracellular levels of enzyme activity had >10-fold differences in activity in the medium. Yet, as noted with recombinant production of other lysosomal enzymes (24, 25), this increased secretory characteristic did not involve other, endogenous lysosomal enzymes. Similar to what has been observed with transiently transfected COS cells (4), the medium contained only the 110-kDa precursor enzyme even under optimized culture conditions. The broad bands on SDS/polyacrylamide gels suggest a microheterogeneous glycoprotein. After deglycosylation, two sharp bands in the region of 95 kDa were seen, confirming not only the extensive contribution of glycosylation but also the underlying heterogeneity in protein size. The secreted form in COS cells starts at His-29, corresponding to cleavage of the leader peptide (4). We have not ascertained whether the difference in these two bands reflects a difference in start site (e.g., with or without loss of the leader peptide) or in the carboxyl-terminal position. Intracellularly, the CHO cells contained typical intermediates of 90 and 76 kDa, but not the 67-kDa form seen in fibroblasts, and little of the 1 10-kDa form seen in transiently transfected COS cells (4). The purified 
